Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Derma Pen, LLC Appoints New Medical Director for Dermapen Products

September 29, 2012

Derma Pen, LLC announced today that Dr. Mike Johnson has joined the company as Medical Director for its Dermapen products.

Salt Lake City, Utah (PRWEB) September 28, 2012

Derma Pen, LLC announced today that Dr. Mike Johnson has joined the company as Medical Director for its Dermapen products. Mike Johnson M.D. trained as a neurologist at the University of Minnesota. After postdoctoral training, he pursued neuroscience research in Parkinson´s disease and basic motor physiology. Concurrently with his academic research activities, Dr. Johnson developed iontophoresis drug delivery, wound healing, and neuromuscular stimulation devices in consultation with industry. He has published numerous basic science papers and holds patents pertaining to drug delivery and neuromuscular control.

Dr. Johnson began working with the cosmetic – dermatological industry over 10 years ago as an Intense Pulsed Light (IPL) and laser developer. Having extensive previous experience with fractional lasers, Dr. Johnson found Dermapen to be a highly competitive solution. He states, Needle dermabrasion has an impressive scientific literature base, without a single reported case of post-treatment post-inflammatory hyperpigmentation, so common after laser-based therapies. Dermapen induces collagenesis without coagulating capillaries and leaving charred, necrotic debris in the micro-wounds. It appears to do this without inflammation”

Find Dermapen on Facebook at http://www.Facebook.com/Dermapen.

Dr. Johnson has well-honed expertise in medical device regulatory affairs for the U.S. and International markets. “We´re looking at exciting clinical trials ahead for Dermapen products. I am excited to be involved in the process of developing new indications for Dermapen and obtaining clearance by the FDA and CE/MDD.”

“Dr. Johnson´s wealth of industry knowledge and experience has already made him a key addition to the Dermapen family. We are more than excited to have him as our Medical Director as we look to stay ahead of this emerging market. Our current Dermapen and Cosmetic Products as well as new innovations in skin evaluation are currently in development, paired with increasing demand from our growing practitioners led us to look for a skilled medical director who understood the incredible opportunities in the field of skin micro needling. We have found that medical director in Dr. Mike Johnson,” says Mike Morgan, CEO.

For more information about Dermapen, please call (800) 981-5402, email Info(at)Dermapen(dot)com, or visit us online at http://www.Dermapen.com. Follow Dermapen on Twitter at http://www.Twitter.com/Dermapen.

Derma Pen, LLC is a cosmetic marketing company that trademarks, brands, and distributes cosmetic equipment. The Dermapen® device and its products are sold directly to plastic surgeons, dermatologist, physician and medical spa markets. The device has been designed and manufactured with the cumulative effort of leading technicians and experts in multiple countries. The market segments are defined as licensed estheticians, medical spas and retreats, dermatologist offices and related cosmetic surgeon practices. According to new market research, the global market for cosmetic surgery services will reach the $40 billion mark by the year 2013, up from $31.7 billion in 2008, for a compound annual growth rate of 5.2%. In another study, the market for cosmetic surgery, facial aesthetics and medical laser devices is expected to almost double in size, exceeding $3 billion by 2017. Aesthetic laser and light therapy markets for skin resurfacing, hair removal and laser lipolysis are the fastest growing segments. Additional market analysis provides a well-defined and unanswered need in stretch mark therapy. The new and innovative design of the Dermapen has been shown to answer the needs for the successful treatment of this problem.

View Dermapen in action on YouTube at http://www.YouTube.com/Dermapen.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/9/prweb9943859.htm


Source: prweb